Personality and adherence to antiretroviral therapy in HIV-infected adult patients. 2021

Daniel Hernández-Huerta, and Carlos Parro-Torres, and Agustín Madoz-Gúrpide, and María Jesús Pérez-Elías, and Santiago Moreno-Guillén, and Enriqueta Ochoa-Mangado
Department of Psychiatry, Ramón y Cajal University Hospital, Madrid, Spain. Electronic address: daniel.hernandez@salud.madrid.org.

Antiretroviral therapy (ART) has been able to transform HIV infection into a chronic disease. However, ART adherence remains an important barrier and personality traits have been postulated as a factor to be considered. This study aims to identify personality traits that can affect ART adherence, taking into account other potentially influencing factors. Case-control study. Controls and cases were classified using the percentage ART dispensation as recorded in the Hospital Pharmacy database. Controls were defined as people living with HIV/AIDS (PLWHA) with percentage ART dispensation during the last year >95% and cases were defined as PLWHA with percentage ART dispensation during the last year <90%. Sociodemographic, clinical parameters of HIV infection, psychopathological and neuropsychological factors were collected. Personality was assessed using the NEO PI-R Personality Inventory, questionnaire based on the Five Factor Model of Personality. Statistical analysis was performed using logistic regression (SPSS v.22). 125 PLWHA were included: 79 controls and 46 cases. After adjusting for confounding variables, logistic regression analysis showed that poor adherence was associated with Neuroticism (OR 1.2, 95%CI: 1.021-1.385) and Impulsivity (N5) (OR 1.5, 95%CI: 1.066-2.163). In contrast, each additional point in Order (C2) (OR 0.8, 95%CI: 0.679-0.992) or Values (O6) (OR 0.8, 95%CI: 0.710-0.974) were associated with good ART adherence. Personality is a variable to be considered in ART adherence. Implementation of the personality in the assessment of PLWHA helps identify those individuals potentially more likely to exhibit poorer ART adherence.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010551 Personality Behavior-response patterns that characterize the individual. Personalities
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D044966 Anti-Retroviral Agents Agents used to treat RETROVIRIDAE INFECTIONS. Antiretroviral Agent,Antiretroviral Agents,Agent, Antiretroviral,Agents, Anti-Retroviral,Agents, Antiretroviral,Anti Retroviral Agents
D055118 Medication Adherence Voluntary cooperation of the patient in taking drugs or medicine as prescribed. This includes timing, dosage, and frequency. Drug Adherence,Drug Compliance,Medication Compliance,Medication Nonadherence,Medication Non-Adherence,Medication Non-Compliance,Medication Noncompliance,Medication Persistence,Adherence, Drug,Adherence, Medication,Compliance, Drug,Compliance, Medication,Medication Non Adherence,Medication Non Compliance,Non-Adherence, Medication,Non-Compliance, Medication,Nonadherence, Medication,Noncompliance, Medication,Persistence, Medication

Related Publications

Daniel Hernández-Huerta, and Carlos Parro-Torres, and Agustín Madoz-Gúrpide, and María Jesús Pérez-Elías, and Santiago Moreno-Guillén, and Enriqueta Ochoa-Mangado
December 1994, Der Internist,
Daniel Hernández-Huerta, and Carlos Parro-Torres, and Agustín Madoz-Gúrpide, and María Jesús Pérez-Elías, and Santiago Moreno-Guillén, and Enriqueta Ochoa-Mangado
June 1998, AIDS (London, England),
Daniel Hernández-Huerta, and Carlos Parro-Torres, and Agustín Madoz-Gúrpide, and María Jesús Pérez-Elías, and Santiago Moreno-Guillén, and Enriqueta Ochoa-Mangado
January 2012, Medecine et sante tropicales,
Daniel Hernández-Huerta, and Carlos Parro-Torres, and Agustín Madoz-Gúrpide, and María Jesús Pérez-Elías, and Santiago Moreno-Guillén, and Enriqueta Ochoa-Mangado
November 2001, Journal of acquired immune deficiency syndromes (1999),
Daniel Hernández-Huerta, and Carlos Parro-Torres, and Agustín Madoz-Gúrpide, and María Jesús Pérez-Elías, and Santiago Moreno-Guillén, and Enriqueta Ochoa-Mangado
September 2013, Le infezioni in medicina,
Daniel Hernández-Huerta, and Carlos Parro-Torres, and Agustín Madoz-Gúrpide, and María Jesús Pérez-Elías, and Santiago Moreno-Guillén, and Enriqueta Ochoa-Mangado
January 2020, AIDS (London, England),
Daniel Hernández-Huerta, and Carlos Parro-Torres, and Agustín Madoz-Gúrpide, and María Jesús Pérez-Elías, and Santiago Moreno-Guillén, and Enriqueta Ochoa-Mangado
January 2012, AIDS research and treatment,
Daniel Hernández-Huerta, and Carlos Parro-Torres, and Agustín Madoz-Gúrpide, and María Jesús Pérez-Elías, and Santiago Moreno-Guillén, and Enriqueta Ochoa-Mangado
July 2001, International journal of STD & AIDS,
Daniel Hernández-Huerta, and Carlos Parro-Torres, and Agustín Madoz-Gúrpide, and María Jesús Pérez-Elías, and Santiago Moreno-Guillén, and Enriqueta Ochoa-Mangado
June 2017, Journal of pharmacy practice,
Daniel Hernández-Huerta, and Carlos Parro-Torres, and Agustín Madoz-Gúrpide, and María Jesús Pérez-Elías, and Santiago Moreno-Guillén, and Enriqueta Ochoa-Mangado
December 1999, AIDS care,
Copied contents to your clipboard!